Anthropic buys one-person biotech Mithril Medicine for in-house drug discovery

Anthropic's disclosure comes alongside progress reports on partnerships with six organizations working on new drugs, and it follows the June 30 launch of Claude Science, a research-oriented AI work environment. At that time Anthropic said it would pursue its own drug discovery, focusing on diseases traditional pharma and biotech companies have found unattractive and on preclinical research before human testing.

The Mithril case illustrates that approach: Traumberger used Claude to read 341 pages of manufacturing data and sort 113 candidate antibodies into test, re-purify, or hold within under eight minutes, and the AI also drafted emails to contract research organizations. The limits are visible too. Anthropic's technical report notes that human review caught judgment errors about which candidates to test but tended to miss details like quantities, and at least three flawed requests slipped through.

Traumberger has moved to Anthropic and plans several new drug discovery programs. The acquired work targets LAMA2-related congenital muscular dystrophy, a pediatric disease with no fundamental treatment, using a bispecific antibody that bridges a remaining muscle protein to muscle fibers; the same mechanism may also apply to alpha-dystroglycanopathy.